KCI Biotech (SUZHOU) Inc. (KCI) and Jiangsu KMQ biotech Inc. (KMQ) which is a wholly-owned subsidiary of KCI are preclinical Contract Research Organization (CRO) providing specialty preclinical pharmacology services. With professional integrated R&D team and rich experience in pharmacology, KCI grabbed a large slice of market share in preclinical research field with high technical barriers and huge demand. KCI has cooperated with more than 300 pharmaceutical R&D companies, and completed more than 50 domestic and international investigational new drug application projects.